全文获取类型
收费全文 | 3257篇 |
免费 | 257篇 |
国内免费 | 79篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 139篇 |
妇产科学 | 10篇 |
基础医学 | 296篇 |
口腔科学 | 6篇 |
临床医学 | 370篇 |
内科学 | 889篇 |
皮肤病学 | 9篇 |
神经病学 | 62篇 |
特种医学 | 83篇 |
外科学 | 917篇 |
综合类 | 395篇 |
现状与发展 | 2篇 |
预防医学 | 68篇 |
眼科学 | 11篇 |
药学 | 193篇 |
2篇 | |
中国医学 | 101篇 |
肿瘤学 | 39篇 |
出版年
2023年 | 89篇 |
2022年 | 126篇 |
2021年 | 221篇 |
2020年 | 144篇 |
2019年 | 173篇 |
2018年 | 176篇 |
2017年 | 131篇 |
2016年 | 137篇 |
2015年 | 148篇 |
2014年 | 210篇 |
2013年 | 213篇 |
2012年 | 146篇 |
2011年 | 147篇 |
2010年 | 130篇 |
2009年 | 110篇 |
2008年 | 124篇 |
2007年 | 114篇 |
2006年 | 97篇 |
2005年 | 77篇 |
2004年 | 72篇 |
2003年 | 64篇 |
2002年 | 60篇 |
2001年 | 58篇 |
2000年 | 39篇 |
1999年 | 26篇 |
1998年 | 33篇 |
1997年 | 48篇 |
1996年 | 44篇 |
1995年 | 52篇 |
1994年 | 46篇 |
1993年 | 38篇 |
1992年 | 35篇 |
1991年 | 15篇 |
1990年 | 22篇 |
1989年 | 25篇 |
1988年 | 23篇 |
1987年 | 21篇 |
1986年 | 20篇 |
1985年 | 22篇 |
1984年 | 27篇 |
1983年 | 13篇 |
1982年 | 10篇 |
1981年 | 16篇 |
1980年 | 7篇 |
1979年 | 5篇 |
1978年 | 6篇 |
1977年 | 5篇 |
1976年 | 4篇 |
1975年 | 9篇 |
1974年 | 5篇 |
排序方式: 共有3593条查询结果,搜索用时 15 毫秒
1.
2.
3.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):399-407
PurposeTo evaluate the midterm outcomes of percutaneous transluminal renal angioplasty (PTRA) for pediatric renovascular hypertension (RVH).Materials and MethodsThe clinical data of patients who underwent PTRA for RVH in the authors’ hospital from 2012 to 2019 were retrospectively analyzed. Postprocedural blood pressure, glomerular filtration rate (GFR) of the affected kidney, restenosis, and complications were closely monitored.ResultsPTRA was performed in a total of 30 children (20 boys and 10 girls), with a mean age of 7.3 years ± 0.7 (range, 40 days to 13.9 years) and a mean weight of 25.0 kg ± 2.3 (range, 3.4–53 kg). The median follow-up period was 26.5 months (range, 1 month to 7.5 years). Technical success was achieved in 26 (86.7%) of the 30 patients. Restenosis developed in 3 patients (10.0%). Only 1 patient underwent stent implantation, and the stent fractured 8 months later, requiring further intervention. There were no other complications. In terms of clinical benefit of blood pressure control after the initial PTRA procedure, 15 patients (50%) were cured and 7 patients (23.3%) showed improvement. There was no significant difference in the etiology, lesion location, and lesion length between patients with clinical benefit and failure (P = .06, P = .202, and P = .06, respectively). GFR of the affected kidney was significantly improved from 19.9 mL/min ± 11.2 to 38.1 mL/min ± 11.9 at the 6-month follow-up after PTRA (P < .001).ConclusionsThe overall results of PTRA for pediatric RVH caused by different etiologies are promising. PTRA not only provided a clinical benefit of blood pressure control in 73.3% of the patients but also significantly improved the function of the affected kidney. 相似文献
4.
5.
6.
7.
Lesley A. Inker Morgan E. Grams Andrew S. Levey Josef Coresh Massimo Cirillo John F. Collins Ron T. Gansevoort Orlando M. Gutierrez Takayuki Hamano Gunnar H. Heine Shizukiyo Ishikawa Sun Ha Jee Florian Kronenberg Martin J. Landray Katsuyuki Miura Girish N. Nadkarni Carmen A. Peralta Dietrich Rothenbacher Mark Woodward 《American journal of kidney diseases》2019,73(2):206-217
8.
《Drug metabolism and pharmacokinetics》2019,34(1):87-94
The purpose of this study was to elucidate the involvement of Mate1 in the tubular secretion of trimethoprim and saturation of Mate1-mediated efflux to address the mechanisms underlying the pharmacokinetic drug interactions with trimethoprim. Trimethoprim is a more potent inhibitor of MATE2-K than MATE1 with Ki values (μM) of 0.030–0.28 and 2.4–5.9, respectively. Trimethoprim is a substrate of human MATE1 and MATE2-K with Km values of 2.3 ± 0.9 and 0.018 ± 0.004 μM, and mouse Mate1, but not human OCT2, mouse Oct1 and Oct2. Pyrimethamine significantly reduced the renal clearance (CLR) of trimethoprim (mL/min/kg) from 40.0 ± 5.1 to 20.1 ± 3.7 (p < 0.05). Trimethoprim was given to mice at three infusion rates (150, 500, and 1500 nmol/min/kg). Together with an increase in the plasma concentrations of trimethoprim, the CLR (mL/min/kg) of trimethoprim decreased to 25.9 ± 3.2, 13.5 ± 5.7, and 8.92 ± 1.50 at the respective rates. Trimethoprim decreased the CLR of rhodamine 123 in an infusion rate-dependent manner: 11.5 ± 1.3 (control), 5.17 ± 1.55, 1.31 ± 0.50, and 0.532 ± 0.180. These results suggest that Mate1 mediates the tubular secretion of trimethoprim, and at therapeutic doses, MATEs-mediated efflux can be saturated, and thereby, cause drug interactions with other MATE substrates. 相似文献
9.
10.